N. K. Koltzov Institute of Developmental Biology RAS , 26 Vavilov Street , 119334 Moscow , Russian Federation.
N. D. Zelinsky Institute of Organic Chemistry RAS , 47 Leninsky Prospect , 119991 Moscow , Russian Federation.
ACS Comb Sci. 2018 Dec 10;20(12):700-721. doi: 10.1021/acscombsci.8b00113. Epub 2018 Nov 29.
A series of both novel and reported combretastatin analogues, including diarylpyrazoles, -isoxazoles, -1,2,3-triazoles, and -pyrroles, were synthesized via improved protocols to evaluate their antimitotic antitubulin activity using in vivo sea urchin embryo assay and a panel of human cancer cells. A systematic comparative structure-activity relationship studies of these compounds were conducted. Pyrazoles 1i and 1p, isoxazole 3a, and triazole 7b were found to be the most potent antimitotics across all tested compounds causing cleavage alteration of the sea urchin embryo at 1, 0.25, 1, and 0.5 nM, respectively. These agents exhibited comparable cytotoxicity against human cancer cells. Structure-activity relationship studies revealed that compounds substituted with 3,4,5-trimethoxyphenyl ring A and 4-methoxyphenyl ring B displayed the highest activity. 3-Hydroxy group in the ring B was essential for the antiproliferative activity in the diarylisoxazole series, whereas it was not required for potency of diarylpyrazoles. Isoxazoles 3 with 3,4,5-trimethoxy-substituted ring A and 3-hydroxy-4-methoxy-substituted ring B were more active than the respective pyrazoles 1. Of the azoles substituted with the same set of other aryl pharmacophores, diarylpyrazoles 1, 4,5-diarylisoxazoles 3, and 4,5-diaryl-1,2,3-triazoles 7 displayed similar strongest antimitotic antitubulin effect followed by 3,4-diarylisoxazoles 5, 1,5-diaryl-1,2,3-triazoles 8, and pyrroles 10 that showed the lowest activity. Introduction of the amino group into the heterocyclic core decreased the antimitotic antitubulin effect of pyrazoles, triazoles, and to a lesser degree of 4,5-diarylisoxazoles, whereas potency of the respective 3,4-diarylisoxazoles was increased.
一系列新型和已报道的 combretastatin 类似物,包括二芳基吡唑、异噁唑、1,2,3-三唑和吡咯,通过改进的方案合成,以使用体内海胆胚胎测定和一系列人类癌细胞评估其抗有丝分裂抗微管蛋白活性。对这些化合物进行了系统的比较结构-活性关系研究。吡唑 1i 和 1p、异噁唑 3a 和三唑 7b 在所有测试化合物中显示出最强的抗有丝分裂活性,分别在 1、0.25、1 和 0.5 nM 时导致海胆胚胎的分裂改变。这些试剂对人类癌细胞表现出相当的细胞毒性。结构-活性关系研究表明,化合物取代 A 环的 3,4,5-三甲氧基苯基和 B 环的 4-甲氧基苯基显示出最高的活性。B 环上的 3-羟基对于二芳基异噁唑系列的抗增殖活性是必需的,而对于二芳基吡唑则不需要。取代 A 环的 3,4,5-三甲氧基和 B 环的 3-羟基-4-甲氧基的异噁唑 3 比相应的吡唑 1 更具活性。在具有相同一组其他芳基药效团取代的唑类中,二芳基吡唑 1、4,5-二芳基异噁唑 3 和 4,5-二芳基-1,2,3-三唑 7 显示出相似的最强抗有丝分裂抗微管蛋白作用,其次是 3,4-二芳基异噁唑 5、1,5-二芳基-1,2,3-三唑 8 和吡咯 10,其活性最低。杂环核心中引入氨基会降低吡唑、三唑和在较小程度上降低 4,5-二芳基异噁唑的抗有丝分裂抗微管蛋白作用,而相应的 3,4-二芳基异噁唑的活性增强。